Continuing Medical Education (CME) Credit
The American Society of Pediatric Hematology/Oncology’s 29th Annual Meeting will offer CME credit for those sessions attended and evaluated. A certificate will be issued upon receipt of submission of the evaluation.
The American Society of Pediatric Hematology/Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.
The American Society of Pediatric Hematology/Oncology designates this live activity for a maximum of 21 AMA PRA Category 1 Creditstm. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ASPHO offers its meeting evaluation in an online format. Meeting registrants can access the evaluation by visiting www.aspho.org/annualmeeting. The online evaluation may be completed during the meeting or after attendees have returned home. Participants will receive their certificate immediately when they submit their evaluations online. We encourage all attendees to complete this evaluation regardless of whether they are seeking CME credits. For more information, visit www.aspho.org/annualmeeting or call 847.375.4716.
Intended Audience and Purpose
The Annual Meeting of the American Society of Pediatric Hematology/Oncology is designed to provide residents, fellows, investigators, and practitioners involved in the dynamic and rapidly evolving discipline of pediatric hematology/oncology with state-of-the-art education in the subspecialty.
The participant will be able to:
- Comprehend new information in pediatric hematology/oncology, including the latest in basic and clinical research.
- Apply knowledge gained in all areas of pediatric hematology/oncology investigation and practice.
- Assemble a network of professional colleagues with whom you can solve problems, share experiences, and provide mutual professional support.
Specifically, at the end of the meeting, we expect participants will be better prepared in areas of:
- Career Development: Be familiar with issues that are critical to early-, mid- and late-career pediatric hematologists and oncologists—negotiation, financial management, transitions, and successions.
- Oncology: Describe recent advances in the biology and therapy of Wilms, thyroid, and neuroendocrine tumors and melanomas.
- Molecular Diagnostics: Identify recent advances in the role of exosomes in tumor diagnosis and disease monitoring.
- Hematopoietic Stem Cell Transplantation: Discuss the pathophysiology and treatment options for sinusoidal obstruction syndrome (SOS) and recognize the optimal hematopoietic stem cell transplantation (HSCT) timing and indications for HSCT in sickle cell disease patients.
- Novel Therapeutics: Identify novel therapeutic options for patients with recurrent/refractory acute lymphoblastic leukemia.
- Hematology: Recognize the availability of novel therapies for bleeding disorders, hemoglobinopathies, and red blood cell enzymopathies, and discuss novel management approaches for immune cytopenias and hemophagocytic lymphohistiocytosis.
- AYA Oncology: Identify end-of-life care needs and experiences unique to adolescents and young adults with cancer and their families.
- Neuro-Oncology: Summarize recent developments in understanding novel advances in pediatric brain tumor biology and therapy.
- Hematology/Oncology Emergencies: Identify approaches to managing potential life-threatening events in pediatric hematology and oncology patients.
- Regulation: Discuss how the Food and Drug Administration (FDA) develops new cancer treatments, and understand the process for obtaining authorization for investigational new drug applications for clinical trials.
- Survivorship: Summarize recent developments in the care of childhood cancer survivors.
ASPHO requires that planners and presenters disclose the existence of any relevant financial or other relationship they and/or their spouse/partner have with the manufacturers of any commercial interest (defined as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by, or used on, patients) whose products or services relate to the topics presented. ASPHO also requires disclosure of the intent to discuss unlabeled or investigational use(s) of a commercial product. The Certification and Continuing Education Committee reviews potential conflicts of interest as submitted by planners and presenters and resolves such conflicts to ensure the content of the activity is aligned with the interests of the public.
The material presented in this activity represents the opinion of the speakers and not necessarily the views of ASPHO.
Educational Support Acknowledgement
ASPHO extends its appreciation to the following organizations for their educational support of the Annual Meeting:
- Amgen, Inc.
- Pfizer Inc.
- Bayer Healthcare
- Novartis Pharmaceuticals